Citigroup’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Citigroup’s Portfolio RPTP Stock Details RPTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-10,300	Closed	-$92K	–	7562
2016 Q3	$92K	Sell	10,300 -1,200	-10%	-$8.53K	﹤0.01%	5261
2016 Q2	$62K	Buy	11,500 +4,900	+74%	+$25.1K	﹤0.01%	5432
2016 Q1	$30K	Sell	6,600 -5,800	-47%	-$23.3K	﹤0.01%	6367
2015 Q4	$64K	Sell	12,400 -30,600	-71%	-$178K	﹤0.01%	5744
2015 Q3	$260K	Buy	43,000 +34,000	+378%	+$417K	﹤0.01%	4303
2015 Q2	$142K	Buy	9,000 +1,000	+13%	+$12.1K	﹤0.01%	4730
2015 Q1	$87K	Buy	+8,000	New	+$81.7K	﹤0.01%	5132

Citigroup's RPTP Position: Q4 2016 in Review

Citigroup sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 51,137 shares — an estimated $459K sold.

Citigroup first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $731K in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.

Citigroup reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
Citigroup sold 51,137 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $459K.
Citigroup first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
Citigroup's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $731K in Q2 2015.
0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.

Based on Citigroup's 13F filing for Q4 2016, filed 10 Feb 2017.